VANECK BIOTECH ETF

NASDAQ: BBH
$153.91
-$1.21 (-0.8%)
Closing price April 16, 2024
VanEck Biotech ETF is a fund that focuses on the biotech sector, investing in a mix of growth and value stocks across various market sizes in the U.S. It aims to mirror the performance of the MVIS US Listed Biotech 25 Index, primarily targeting companies in health care, pharmaceuticals, biotechnology, and life sciences. Managed by Van Eck Associates Corporation, this ETF offers investors exposure to the biotech industry's potential for innovation and growth.
Shares of five top established and mature biotechnology and pharmaceutical companies have been hit hard and are offering some of the best entry points in months. The stocks also are rated Buy at top...
The 55th annual meeting of the American Society of Clinical Oncology (ASCO) is just around the corner. Biotech and pharmaceutical companies will descend on Chicago for a five-day all-out conference...
The biotech team at SunTrust feel that it would not be a major surprise to see these six top companies post quarterly results that beat top-line Wall Street expectations.
Source: Jon OggBiotech stocks come and go as far as the flavor of the day for investors. While many of these companies are risky, and while many are too risky for many investors, what investors need...
Source: Thinkstock24/7 Wall St. is taking a daily aim at the world exchange-traded funds (ETFs). Many are great, and many are actively traded and truly represent what investors are trying to get...
Source: Thinkstock24/7 Wall St. has always wondered about the confusing universe of biotech exchange-traded funds (ETFs). Biotech stocks can rise or fall regardless of the market direction, and the...
Index changes are generally speaking a fairly routine event.  They can also create underlying moves in the companies added and deleted from them as money management firms often buy and sell shares,...
We have compiled a detailed list of expected upside in the biotech sector.  The sector has consolidated and now there is about to be a rush of earnings reports from tomorrow’s emerging drug...
Biotech is becoming the ever-shrinking stock sector.  It is almost weekly now that a new biotech acquisition is announced.  Big Pharma in the United States and large drugmakers internationally...
The proposed buyout of Genzyme Corporation (NASDAQ: GENZ) by Sanofi-Aventis (NYSE: SNY) should close this week.  We are about to get a new Genzyme security on the market and that will be the...
Futurists are an odd lot.  Generally, they are authors, scientists,  consultants and economists.  What many people don’t know is that investors follow this philosophy as well.  Their goal is to...
Biotech and emerging pharma both seem to have almost no friends today despite a large stock market rally.  It may take a resolution of the Genzyme Corporation (NASDAQ: GENZ) merger, and a successful...
Today’s version of the BioHealth Business Daily is rather different as we have a big disappointment from one of the top biotech operations in the world.  BioHealth stocks moving on news and after...
Here are some of today’s top stories affecting key drug and biotech stocks, accompanied with links through to more detailed information and analysis at BioHealthInvestor.com: New short-interest...
Biotech’s are sliding along with all the others today. A look at the highlights and outliers: Amgen (NASDAQ: AMGN) and Wyeth (NYSE: WYE) announced that arthritis and psoriasis drug Enbrel will now...